Dacetuzumab clinical trials
Also written SGN-40.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How each study uses dacetuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses dacetuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 1Genentech, Inc.NCT00664898Written as SGN-40
- A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCLTerminatedPhase 2Seagen Inc.NCT00529503Written as SGN-40
- Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell LymphomaCompletedPhase 2Seagen Inc.NCT00435916Written as SGN-40
- A Safety Study in Patients With Chronic Lymphocytic LeukemiaCompletedPhase 1/2Seagen Inc.NCT00283101Written as SGN-40 (anti-huCD40 mAb)
- Study of SGN-40 in Patients With Refractory or Recurrent Multiple MyelomaCompletedPhase 1Seagen Inc.NCT00079716Written as SGN-40 (anti-huCD40 mAb)
- Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCLCompletedPhase 1Seagen Inc.NCT00655837Written as SGN-40
- A Safety Study of SGN-40 in Patients With Non-Hodgkin's LymphomaCompletedPhase 1Seagen Inc.NCT00103779Written as SGN-40 (anti-huCD40 mAb)
- Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple MyelomaCompletedPhase 1Seagen Inc.NCT00525447Written as SGN-40
- A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's LymphomaCompletedPhase 1Genentech, Inc.NCT00556699Written as SGN-40
Codes
What other systems call dacetuzumab · ClinicalTrials.gg INT005484
- MeSH (NLM) C543331dacetuzumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) UT59FF4T5XDACETUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q953025dacetuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62179DacetuzumabOne source FDA
- DrugBank DB12589One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C543331 | dacetuzumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | UT59FF4T5X | DACETUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q953025 | dacetuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62179 | Dacetuzumab | One source FDA |
| DrugBank | DB12589 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.